A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2018
At a glance
- Drugs ACH 4471 (Primary) ; Eculizumab
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 10 May 2018 Status changed from not yet recruiting to recruiting.
- 26 Mar 2018 Planned initiation date changed from 31 Mar 2018 to 15 Apr 2018.
- 15 Mar 2018 Status changed from planning to not yet recruiting.